Tuberculosis Diagnostics: Trends And Competitive Analysis

Tuberculosis (TB) continues to pose a major global health challenge, further complicated by the emergence of extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains. Each year, 10 million people worldwide contract TB, an infectious disease that primarily affects the lungs but can also target other parts of the body. Annually, TB claims 1.5 million lives, making it the leading infectious killer. It is the primary cause of death among people living with HIV and significantly contributes to global antimicrobial resistance.

The trends and competitive analysis report, compiled by Grand View Research, is a collection of the trends and competitive scenario in more than 20 countries. Qualitative information regarding the trends, government initiatives, funding landscape, competitive strategies, existing competition, and pipeline analysis will be provided in the report. Within the purview of the database, such information is systematically analyzed and provided in the form of outlook reports and summary presentations on individual areas of research.

Tuberculosis Diagnostics: Trends And Competitive Analysis Report Scope

Tuberculosis Diagnostics: Trends And Competitive Analysis Coverage Snapshot

Recent trends indicate progress in diagnostics, treatment, and prevention, fueled by technological advancements, regulatory changes, and increased funding. Recognizing the need for innovative approaches to prevent, diagnose, and treat TB to meet the 2030 elimination goal, UN member states made new commitments at the 2023 UN High-Level Meeting on TB. They agreed to raise the annual funding target for TB research to $5 billion by 2027, more than doubling the $2 billion target set in 2018.

The WHO's End TB Strategy underscores the importance of integrating innovative diagnostic tools to improve early and accurate TB detection. Molecular diagnostics, such as the GeneXpert MTB/RIF assay and next-generation sequencing, are crucial for rapidly diagnosing TB and detecting drug resistance. Additionally, in April 2022, the WHO evaluated Tuberculosis antigen-based skin tests (TBST), a new class of tests for diagnosing TB infection. These tests have been found to be feasible, accurate, cost-effective, and acceptable, offering an alternative to the tuberculin skin test (TST) and Interferon-Gamma Release Assays (IGRAs).

FUNDING PROGRAMS TO PROMOTE TB DIAGNOSIS

• The U.S. government has significantly increased its funding for TB initiatives, from USD 233 million in 2013 to USD 406 million in 2023. Investments in TB screening and preventive treatment have shown significant health & economic benefits, with a return on investment of up to USD 39 for every dollar spent. Hence, expanding investments in TB diagnosis programs is essential to improve access to diagnosis, treatment, and prevention to eliminate the TB epidemic by 2030.

• The Global Fund plays a significant role in the fight against TB, contributing 76% of total international funding for TB. By June 2023, it had allocated USD 9.2 billion toward TB prevention and treatment programs. Additionally, an extra USD 1.5 billion was allocated for TB/HIV initiatives, further demonstrating the Global Fund's commitment to addressing the TB epidemic.

In addition to awareness programs and government initiatives, strategic activities by key market players and the launch of technologically advanced products will create lucrative opportunities in the TB diagnostics market.

Currently used diagnostic techniques, recognized by the WHO, with the associated strengths and weaknesses

Recent developments of Novel Technologies

• ddPCR

  • Recent advancements have incorporated emerging technologies such as digital droplet PCR (ddPCR), which partitions the amplification reaction seen in PCR, providing absolute quantification of gene expression with higher sensitivity than qPCR. Capable of detecting single DNA copies, ddPCR has been used to monitor cell populations for drug resistance and can test for Mtb infection in sputum and blood samples, making it valuable for pulmonary, extrapulmonary, LTBI, and active TB. However, its primary drawback is its prohibitive cost.

• CRISPR

• Next-generation sequencing techniques

• MicroRNA detection

• eNose

• Raman spectroscopy

• AI processing